Consensus Recommendations for the Clinical Management of
Hematological Malignancies in Patients with DNA Double Stranded
Break Disorders

J 2022

Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders

PASTORCZAK, Agata, Andishe ATTARBASCHI, Simon BOMKEN, Arndt BORKHARDT, van der Werff ten Bosch JUTTE et. al.

Základní údaje

Originální název

Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders

Autoři

PASTORCZAK, Agata (garant), Andishe ATTARBASCHI, Simon BOMKEN, Arndt BORKHARDT, van der Werff ten Bosch JUTTE, Sarah ELITZUR, Andrew R GENNERY, Eva HLAVÁČKOVÁ (203 Česká republika, domácí), Arpád KEREKES (703 Slovensko, domácí), Zdenka KŘENOVÁ (203 Česká republika, domácí), Wojciech MLYNARSKI, Tomasz SZCZEPANSKI, Tessa WASSENBERG a Jan LOEFFEN

Vydání

Cancers, Basel, MDPI, 2022, 2072-6694

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.200

Kód RIV

RIV/00216224:14110/22:00128354

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3390/cancers14082000

UT WoS

000786061500001

Klíčová slova anglicky

DNA repair disorder; Ataxia Telangiectasia; Nijmegen breakage syndrome; leukemia; lymphoma; clinical management

Štítky

14110114, 14110321, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 19. 2. 2024 10:51, Mgr. Tereza Miškechová

Anotace

V originále

Simple Summary Ataxia Telangiectasia (AT) and Nijmegen breakage syndrome (NBS) are the most common DNA repair disorders (DNARDs), characterized by an exceedingly high risk for developing hematological malignancies and poor outcomes. Clinical management of lymphoproliferative diseases in AT and NBS is complicated due to the competing challenges of delivery of optimal cancer treatment and management of excessive toxicities. AT and NBS are rare genetic entities in the general population, thus gaining extensive experience in treatment of these patients is difficult. Additionally, no treatment guidelines for lymphoproliferative diseases have been specifically designed for this group of patients as yet. In this review we formulate clinical recommendations, considering the most critical aspects related to the management of lymphoproliferative disorders in AT and NBS and we concisely present the current state of knowledge about the biology and outcomes of leukemia and lymphoma in these DNARDs. Patients with double stranded DNA repair disorders (DNARDs) (Ataxia Telangiectasia (AT) and Nijmegen Breakage syndrome (NBS)) are at a very high risk for developing hematological malignancies in the first two decades of life. The most common neoplasms are T-cell lymphoblastic malignancies (T-cell ALL and T-cell LBL) and diffuse large B cell lymphoma (DLBCL). Treatment of these patients is challenging due to severe complications of the repair disorder itself (e.g., congenital defects, progressive movement disorders, immunological disturbances and progressive lung disease) and excessive toxicity resulting from chemotherapeutic treatment. Frequent complications during treatment for malignancies are deterioration of pre-existing lung disease, neurological complications, severe mucositis, life threating infections and feeding difficulties leading to significant malnutrition. These complications make modifications to commonly used treatment protocols necessary in almost all patients. Considering the rarity of DNARDs it is difficult for individual physicians to obtain sufficient experience in treating these vulnerable patients. Therefore, a team of experts assembled all available knowledge and translated this information into best available evidence-based treatment recommendations.

Citovat

PASTORCZAK, Agata, Andishe ATTARBASCHI, Simon BOMKEN, Arndt BORKHARDT, van der Werff ten Bosch JUTTE, Sarah ELITZUR, Andrew R GENNERY, Eva HLAVÁČKOVÁ, Arpád KEREKES, Zdenka KŘENOVÁ, Wojciech MLYNARSKI, Tomasz SZCZEPANSKI, Tessa WASSENBERG a Jan LOEFFEN. Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders. Cancers. Basel: MDPI, 2022, roč. 14, č. 8, s. 1-23. ISSN 2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers14082000.

@article{2250971,
   author = {Pastorczak, Agata and Attarbaschi, Andishe and Bomken, Simon and Borkhardt, Arndt and Jutte, van der Werff ten Bosch and Elitzur, Sarah and Gennery, Andrew R and Hlaváčková, Eva and Kerekes, Arpád and Křenová, Zdenka and Mlynarski, Wojciech and Szczepanski, Tomasz and Wassenberg, Tessa and Loeffen, Jan},
   article_location = {Basel},
   article_number = {8},
   doi = {http://dx.doi.org/10.3390/cancers14082000},
   keywords = {DNA repair disorder; Ataxia Telangiectasia; Nijmegen breakage syndrome; leukemia; lymphoma; clinical management},
   language = {eng},
   issn = {2072-6694},
   journal = {Cancers},
   title = {Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders},
   url = {https://www.mdpi.com/2072-6694/14/8/2000},
   volume = {14},
   year = {2022}
}

TY  - JOUR
ID  - 2250971
AU  - Pastorczak, Agata - Attarbaschi, Andishe - Bomken, Simon - Borkhardt, Arndt - Jutte, van der Werff ten Bosch - Elitzur, Sarah - Gennery, Andrew R - Hlaváčková, Eva - Kerekes, Arpád - Křenová, Zdenka - Mlynarski, Wojciech - Szczepanski, Tomasz - Wassenberg, Tessa - Loeffen, Jan
PY  - 2022
TI  - Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders
JF  - Cancers
VL  - 14
IS  - 8
SP  - 1-23
EP  - 1-23
PB  - MDPI
SN  - 20726694
KW  - DNA repair disorder
KW  - Ataxia Telangiectasia
KW  - Nijmegen breakage syndrome
KW  - leukemia
KW  - lymphoma
KW  - clinical management
UR  - https://www.mdpi.com/2072-6694/14/8/2000
N2  - Simple Summary Ataxia Telangiectasia (AT) and Nijmegen breakage syndrome (NBS) are the most common DNA repair disorders (DNARDs), characterized by an exceedingly high risk for developing hematological malignancies and poor outcomes. Clinical management of lymphoproliferative diseases in AT and NBS is complicated due to the competing challenges of delivery of optimal cancer treatment and management of excessive toxicities. AT and NBS are rare genetic entities in the general population, thus gaining extensive experience in treatment of these patients is difficult. Additionally, no treatment guidelines for lymphoproliferative diseases have been specifically designed for this group of patients as yet. In this review we formulate clinical recommendations, considering the most critical aspects related to the management of lymphoproliferative disorders in AT and NBS and we concisely present the current state of knowledge about the biology and outcomes of leukemia and lymphoma in these DNARDs. Patients with double stranded DNA repair disorders (DNARDs) (Ataxia Telangiectasia (AT) and Nijmegen Breakage syndrome (NBS)) are at a very high risk for developing hematological malignancies in the first two decades of life. The most common neoplasms are T-cell lymphoblastic malignancies (T-cell ALL and T-cell LBL) and diffuse large B cell lymphoma (DLBCL). Treatment of these patients is challenging due to severe complications of the repair disorder itself (e.g., congenital defects, progressive movement disorders, immunological disturbances and progressive lung disease) and excessive toxicity resulting from chemotherapeutic treatment. Frequent complications during treatment for malignancies are deterioration of pre-existing lung disease, neurological complications, severe mucositis, life threating infections and feeding difficulties leading to significant malnutrition. These complications make modifications to commonly used treatment protocols necessary in almost all patients. Considering the rarity of DNARDs it is difficult for individual physicians to obtain sufficient experience in treating these vulnerable patients. Therefore, a team of experts assembled all available knowledge and translated this information into best available evidence-based treatment recommendations.
ER  -

PASTORCZAK, Agata, Andishe ATTARBASCHI, Simon BOMKEN, Arndt BORKHARDT, van der Werff ten Bosch JUTTE, Sarah ELITZUR, Andrew R GENNERY, Eva HLAVÁČKOVÁ, Arpád KEREKES, Zdenka KŘENOVÁ, Wojciech MLYNARSKI, Tomasz SZCZEPANSKI, Tessa WASSENBERG a Jan LOEFFEN. Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders. \textit{Cancers}. Basel: MDPI, 2022, roč.~14, č.~8, s.~1-23. ISSN~2072-6694. Dostupné z: https://dx.doi.org/10.3390/cancers14082000.

Podrobný výpis o publikaci